Advertisement
UK markets closed

  • FTSE 100

    7,895.85
    +18.80 (+0.24%)
     

  • FTSE 250

    19,391.30
    -59.37 (-0.31%)
     

  • AIM

    745.67
    +0.38 (+0.05%)
     

  • GBP/EUR

    1.1619
    -0.0064 (-0.55%)
     

  • GBP/USD

    1.2379
    -0.0059 (-0.48%)
     

  • Bitcoin GBP

    51,902.22
    +784.55 (+1.53%)
     

  • CMC Crypto 200

    1,379.69
    +67.07 (+5.11%)
     

  • S&P 500

    4,983.18
    -27.94 (-0.56%)
     

  • DOW

    37,984.13
    +208.75 (+0.55%)
     

  • CRUDE OIL

    83.60
    +0.87 (+1.05%)
     

  • GOLD FUTURES

    2,414.30
    +16.30 (+0.68%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

  • HANG SENG

    16,224.14
    -161.73 (-0.99%)
     

  • DAX

    17,737.36
    -100.04 (-0.56%)
     

  • CAC 40

    8,022.41
    -0.85 (-0.01%)
     
Property:

11 beautiful homes with glorious garden rooms

Investing in a home with a garden room will enable you to enjoy your outside space whatever the weather

Should You Buy Puma Biotechnology (PBYI) Ahead of Earnings?

Zacks Equity Research
Updated

Investors are always looking for stocks that are poised to beat at earnings season and Puma Biotechnology Inc PBYI may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.

That is because Puma Biotechnology is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a pretty good indicator of some favorable trends underneath the surface for PBYI in this report.

In fact, the Most Accurate Estimate for the current quarter is currently at a loss of $2.24 per share for PBYI, compared to a broader Zacks Consensus Estimate of a loss of $2.75 per share. This suggests that analysts have very recently bumped up their estimates for PBYI, giving the stock a Zacks Earnings ESP of +18.47% heading into earnings season.

Puma Biotechnology Inc Price and EPS Surprise

Puma Biotechnology Inc Price and EPS Surprise | Puma Biotechnology Inc Quote

Why is this Important?

A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises, and outperforming the market. Our recent 10-year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank #3 (Hold) or better show a positive surprise nearly 70% of the time, and have returned over 28% on average in annual returns (see more Top Earnings ESP stocks here).

Given that PBYI has a Zacks Rank #3 and an ESP in positive territory, investors might want to consider this stock ahead of earnings. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

ADVERTISEMENT

Clearly, recent earnings estimate revisions suggest that good things are ahead for Puma Biotechnology, and that a beat might be in the cards for the upcoming report.

Wall Street’s Next Amazon

Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.

Click for details >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Puma Biotechnology Inc (PBYI) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research